Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · IEX Real-Time Price · USD
11.80
+0.46 (4.06%)
Apr 19, 2024, 4:00 PM EDT - Market closed

Company Description

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.

It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E.

Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996.

The company was incorporated in 1996 and is headquartered in Emeryville, California.

Dynavax Technologies Corporation
Dynavax Technologies logo
Country United States
Founded 1996
IPO Date Feb 19, 2004
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 408
CEO Ryan Spencer

Contact Details

Address:
2100 Powell Street, Suite 720
Emeryville, California 94608
United States
Phone (510) 848-5100
Website dynavax.com

Stock Details

Ticker Symbol DVAX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001029142
CUSIP Number 268158201
ISIN Number US2681582019
Employer ID 33-0728374
SIC Code 2834

Key Executives

Name Position
Ryan Spencer Chief Executive Officer, Interim Chief Financial Officer and Director
David F. Novack President and Chief Operating Officer
Dr. Robert Janssen Chief Medical Officer and Senior Vice President of Clinical Development, Medical and Regulatory Affairs
Kelly MacDonald SVice President and Chief Financial Officer (Leave of Absence)
Justin Burgess Principal Accounting Officer and Controller
Jeff P. Coon CHRO and Senior Vice President of Human Resources and Administration
Paul Cox Vice President of Investor Relations and Corporate Communications
John Slebir Senior Vice President and General Counsel
Donn Casale Chief Commercial Officer
Dr. Dong Yu Senior Vice President of Vaccine Research

Latest SEC Filings

Date Type Title
Apr 11, 2024 ARS Filing
Apr 11, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 11, 2024 DEF 14A Other definitive proxy statements
Apr 1, 2024 8-K Current Report
Mar 12, 2024 8-K Current Report
Mar 1, 2024 144 Filing
Feb 22, 2024 10-K Annual Report
Feb 22, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals